Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Gujarat Themis Biosyn Ltd. Share Price
Day's Range
Day's Range
Low
₹410.95
High
₹416.95
Price Summary
| Previous Close | ₹414.20 |
|---|---|
| Day's Range | ₹410.95 - ₹416.95 |
| Open | ₹414.95 |
| 52 Week Range | ₹225.05 - ₹479.00 |
| Volume | 52,642 |
| Market Cap | ₹0.01 |
| Previous Close | ₹414.20 |
|---|---|
| Day's Range | ₹411.05 - ₹416.50 |
| Open | ₹414.05 |
| 52 Week Range | ₹225.75 - ₹479.45 |
| Volume | 5,094 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 218.04 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.16 |
| Price/Earning (TTM) | 110.78 |
| TTM EPS (₹) | 3.74 |
| P/E Ratio | 53.09 |
| Book Value(₹) | 5.14 |
| PAT Margin (%) | 28.15 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 18.16 |
| Trade Value ( ₹ in Lacs) | 21.10 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.16 |
| Price/Earning (TTM) | 110.78 |
| TTM EPS (₹) | 3.74 |
| P/E Ratio | 53.09 |
| Book Value(₹) | 5.14 |
| PAT Margin (%) | 28.15 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 18.16 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 358.73 | 1508.0 |
| Expenses | N/A | N/A |
| PBT | 121.19 | 655.38 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 90.62 | 487.72 |
About Gujarat Themis Biosyn Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | Sachin D Patel |
| NSE Symbol | GUJTHEM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,48,195.77 | 1,862.60 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,50,389.96 | 9,392.65 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,88,966.75 | 4,943.25 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,543.48 | 8,928.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,18,933.76 | 689.50 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,15,860.07 | 1,171.80 | 835.50 - 835.50 |
| Cipla Ltd. | 1,11,888.39 | 1,374.15 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,09,035.01 | 2,016.50 | 823.10 - 823.10 |
| Max Healthcare Institute Ltd. | 1,03,608.88 | 1,057.65 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,00,363.76 | 2,465.65 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Gujarat Themis Biosyn informs about acquisition
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations;), Gujarat Themis Biosyn has informed that the company (GTBL) has completed the acquisition of MicroBiopharm Japan Co., (MBJ), Japan, through its wholly owned subsidiary, Themis Biosyn Japan (TBJ), by making an investment of INR 475 Crores towards capital contribution and INR 745 Crores by way of loan in TBJ. In this regard GTBL has entered into a Loan agreement with TBJ for an amount upto INR 800 Crores on the terms as may be agreed. Details of the agreement are given in annexure 1 attached. A Press release in this respect is attached.
Gujarat Themis Biosyn informs about board meeting outcome
Gujarat Themis Biosyn has informed that pursuant to the approval of the board of directors of the company at its meeting held on August 25, 2026 and approval of the shareholders of the Company by way of a special resolution passed on August 22, 2026, the Board of Directors of the Company, in its meeting held on August 25, 2026, has inter alia considered and approved the following: (i) approval and adoption of the preliminary placement document dated August 25, 2026, and the draft of application form, in connection with the QIP; (ii) authorizing the opening of the proposed Issue of such number of Equity Shares to eligible QIBs through a qualified institutions placement under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) and Section 42 and 62 (1) (c) of the Companies Act, 2013, read with Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, each as amended on August 25, 2026; and (iii) approved the floor price for the QIP, as prescribed under SEBI ICDR Regulations.
The above information is a part of company’s filings submitted to BSE.
Gujarat Themis Biosyn informs about disclosure
Gujarat Themis Biosyn informs about SAST disclosure
Gujarat Themis Biosyn informs about disclosure
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Gujarat Themis Biosyn Ltd. is ₹414.20 as of 2026-09-22.
The market capitalisation of Gujarat Themis Biosyn Ltd. is ₹5,393.49 as of 2026-09-21.
The 1-year return of Gujarat Themis Biosyn Ltd. is 27.90% as of 2026-09-22.
The P/E ratio of Gujarat Themis Biosyn Ltd. is 53.09 as of 2026-09-22.
The 52-week high and low of Gujarat Themis Biosyn Ltd. are ₹479.00 and ₹225.05, respectively, as of 2026-09-22.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
